30 years ago, human immunodeficiency virus (HIV) infection commonly resulted in progression to acquired immunodeficiency syndrome (AIDS), and premature death. Discovery of anti-viral medicines resulted in a better outlook for people infected with this virus. Newer medicines have since built upon these earlier treatments and these newer medicines mean that people infected with the virus have essentially a normal life expectancy. Since life expectancy is extended, the pattern of illness in HIV infected people has probably changed, and this will result in differing costs of care. The purpose of this study is to characterise any changes in outcome and treatment cost in the UK.
Anti-retroviral medicines have evolved over time to the extent that people infected with HIV now survive to full life expectancy. The proposed study is hypothesis generating using a retrospective, cohort design, and intended to provide baseline values to design further studies. Whilst we focus on determining the costs of treating those who are infected with HIV, we will also generate reference values from the general population using matched cases. The primary objective of the study is to characterise the NHS resource use and costs of care of treating people with HIV. Secondarily, epidemiological data will also be characterised in order to understand how these costs are being generated, to examine if/how these have changed over time, and how they compare to the same patterns in the reference cases.
Population demographics
- Resource use and financial costs
- Comorbidity prevalence
- Polypharmacy
- Anti-retroviral treatments (where recorded)
Christopher Morgan - Chief Investigator - Pharmatelligence Limited t/a Human Data Sciences
- Corresponding Applicant -
Sara Jenkins-Jones - Collaborator - Pharmatelligence Limited t/a Human Data Sciences
Sarah Holden - Collaborator - Pharmatelligence Limited t/a Human Data Sciences
Thomas Berni - Collaborator - Pharmatelligence Limited t/a Human Data Sciences
Sara Jenkins-Jones - Collaborator - Pharmatelligence Limited t/a Human Data Sciences
Sarah Holden - Collaborator - Pharmatelligence Limited t/a Human Data Sciences
Thomas Berni - Collaborator - Pharmatelligence Limited t/a Human Data Sciences
HES Admitted Patient Care;HES Outpatient;ONS Death Registration Data